Moratorium on Genetic Testing & Life Insurance: Monitoring the impact
Genetic Testing and Life Insurance
Go to site
Key Aims/Outcomes
The overarching goal of this project is to ensure adequate evidence is collected over the next three years to inform the 2022 FSC review - and help determine the appropriateness of the FSC moratorium as a long-term regulatory solution for the use of genetic test results in life insurance underwriting. The specific aims are to:
- Assess dissemination and awareness of the FSC moratorium, after its implementation in July 2019.
- Determine the impact of the moratorium on healthcare, research and the financial services industry
- Determine the adequacy of the self-regulated FSC moratorium, as a long-term regulatory solution.
School Priorities
Screening and early detection of disease
Project Summary
Our project brings together Australia’s leading researchers, clinicians, patient groups, and policy experts to answer an over-arching research question - is the FSC moratorium an appropriate long-term regulatory solution for Australia? We will address this by collecting quantitative and qualitative data post-moratorium, directly comparable to similar data we collected and published pre-moratorium (baseline). We will have input from consumers, healthcare providers, researchers and the FSC to ensure a study design which captures the opinions and experiences of all key stakeholders.
Funding Sources/Amount
Medical Research Future Fund (MRFF)
$500,000
Project Time Frame
November 2020 to November 2023.
Research Team Members
A/Prof Paul Lacaze - Monash University
Jane Tiller - Monash University
Prof Otlowski - University of Tasmania
Prof Barlow-Steward - University of New South Wales
A/Prof Aideen McInerney-Leo - University of Queensland
Prof Martin Delatycki - Murdoch Children's Research Institute
Prof Louise Keogh - University of Melbourne